Stay updated with breaking news from Abstract Code. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab...
Data supports further development of CYT-338 in relapsed/refractory multiple myeloma
/PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells...
/PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or...
Investegate announcements from Syncona Limited, Autolus to present clinical data at EHA Congress